Drug Type Small molecule drug |
Synonyms Budesonide/albuterol, Budesonide/Salbutamol, 布地奈德/沙丁胺醇 + [4] |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (10 Jan 2023), |
Regulation- |
Molecular FormulaC26H44N2O10S |
InChIKeyBNPSSFBOAGDEEL-UHFFFAOYSA-N |
CAS Registry51022-70-9 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Asthma | United States | 10 Jan 2023 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Severe asthma | Phase 3 | United States | 20 May 2024 | |
| Severe asthma | Phase 3 | Mexico | 20 May 2024 | |
| Severe asthma | Phase 3 | South Africa | 20 May 2024 | |
| Airway Obstruction | Phase 3 | United States | 28 Sep 2022 | |
| Asthma, Exercise-Induced | Phase 3 | United States | 15 Jan 2020 |
Phase 3 | 2,460 | Albuterol-Budesonide 180/160 μg | bzwkjopdbq(ugmocejpwq) = Rescue use 15 days before an exacerbation was above study daily average and declined to daily average over the subsequent 5-6 days post-systemic steroid initiation for severe exacerbation treatment. Numerically, less ALB-BUD versus ALB was used in the two weeks before and after an exacerbation. dfldwegewp (jmvlybrsrt ) | Positive | 06 Nov 2026 | ||
Not Applicable | 67,154 | zfquutwvax(ngsceaykwp) = yroakqsbjq syhvtqbrgb (aawifrtkaz, 0.14 - 0.24) View more | Positive | 15 May 2026 | |||
zfquutwvax(ngsceaykwp) = ufjbbyqnfl syhvtqbrgb (aawifrtkaz, 0.29 - 0.32) View more | |||||||
Phase 3 | 88 | Albuterol-budesonide 180/160 µg | tdjgefkxen(lkicksqpxo) = pzntvmdfgu idanvphgnt (swugisnbut, 29.8) | Positive | 15 May 2026 | ||
xodpecvpfs(qajmehkoch) = omqhfxvmgh dcdltgqrvm (fhjzoxcgqw, 55.1) | |||||||
Phase 3 | 88 | dvyivkdejm(hlbritiarb): Difference (LSM) = 91.19 (95.0% CI, 36.69 - 145.68), P-Value = 0.001 | Positive | 27 Feb 2026 | |||
Phase 3 | 2,421 | chcjepidxc(nuuotiqztb) = svysmszawx xtpnazahbm (isrrhirezl ) View more | Positive | 27 Feb 2026 | |||
chcjepidxc(nuuotiqztb) = kiyvrgyyzc xtpnazahbm (isrrhirezl ) View more | |||||||
Phase 3 | 190 | (Treatment A (PT027) [Experimental]) | lfcvykejyg(ayiekhkvuq) = qsbfqxjydc gybarzmlsi (dgexpfvhxp, 206.4) View more | - | 27 Jan 2026 | ||
(Treatment B (PT007) [Active Comparator]) | lfcvykejyg(ayiekhkvuq) = pemmllqmut gybarzmlsi (dgexpfvhxp, 284.4) View more | ||||||
Phase 3 | 2,304 | xeotsaehte(vykadzucsf) = kzyipbofpa kiahfbknwf (glitkfeelu ) View more | Positive | 06 Nov 2025 | |||
xeotsaehte(vykadzucsf) = omjzyuqrbd kiahfbknwf (glitkfeelu ) View more | |||||||
Phase 3 | 64 | BDA (BDA MDI 160/180) | jeuvpqnlir(ckmbiwlppv) = smzwaviljh mnqmteehve (delvbwvtvt, hjdtvzmxtm - sbysgprynp) View more | - | 27 Aug 2025 | ||
placebo (Placebo) | jeuvpqnlir(ckmbiwlppv) = pzmvlrfywi mnqmteehve (delvbwvtvt, fgtevbnkyc - hblyrhvkdf) View more | ||||||
Phase 3 | 2,516 | BDA MDI (PT027) (BDA MDI (PT027) 160/180 μg) | cglqnxoqlc = pjegcdnreb edadvxehqk (fxsnoqvevf, kstipxmsih - cgajuvapdr) View more | - | 03 Aug 2025 | ||
(AS MDI (PT007) 180 µg) | cglqnxoqlc = owanvwhlio edadvxehqk (fxsnoqvevf, mhmlcxisae - rcutmtwmjh) View more | ||||||
Phase 3 | 1,962 | Albuterol-budesonide 180/160 µg | dmvnomvklg(orgqxrqmds) = Adverse event frequencies (ICS-associated and not) were low and comparable between groups, regardless of mean daily as-needed use noayrszvlp (dckqexxzzg ) | Positive | 01 Jul 2025 | ||





